WuXi and Sinobioway add capacity to nab expected wave of Chinese biologics
admin 17th May 2018 Uncategorised 0China’s new Marketing Authorization Holder program, which allows drugmakers to contract manufacturing instead of building their own plants, appears to have set off a biologics production race of sorts, leading CMOs in China to invest hundreds of millions in new plant projects.
More: WuXi and Sinobioway add capacity to nab expected wave of Chinese biologics
Source: fierce